Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual

摘要: Answer questions and earn CME/CNE The revision of the eighth edition primary tumor, lymph node, metastasis (TNM) classification American Joint Commission Cancer (AJCC) for breast cancer was determined by a multidisciplinary team experts. panel recognized need to incorporate biologic factors, such as tumor grade, proliferation rate, estrogen progesterone receptor expression, human epidermal growth factor 2 (HER2) gene expression prognostic panels into staging system. AJCC levels evidence guidelines all types were followed much possible. felt that, maintain worldwide value, system should remain based on TNM anatomic factors. However, recognition influence hormone HER2 amplification mandated their inclusion value commercially available, gene-based assays acknowledged input added. Tumor biomarkers low Oncotype DX recurrence scores can alter prognosis stage. These updates are expected provide additional precision flexibility extent published information analysis large, yet unpublished databases. system, thus, provides flexible platform traditional which be modified enhanced using patient multifactorial data. remains basis will future online timely relevant. CA J Clin 2017;67:290-303. © 2017 Society.